Nintedinib’s Durable Efficacy in Systemic Sclerosis Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. https://t.co/5M92Yhpeo1 https://t.co/qZvwfLs1jx